Observational studyInternational journal of chronic obstructive pulmonary disease2026
Real-World Identification of Eosinophilic COPD Patients Potentially Eligible for Dupilumab: A Retrospective Observational Study.
Observational study in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite optimized inhaled therapy, many patients with Chronic Obstructive Pulmonary Disease (COPD) continue to experience frequent exacerbations, lung function decline, and impaired quality of life, with severe exacerbations driving disease progression and increasing healthcare costs. Recently, BOREAS & NOTUS studies suggested that a subset of COPD patients with type 2 (T2) inflammation may benefit from biologic therapies. This study aimed to identify COPD patients exhibiting eosinophil-defined T2 inflammatory features potentially responsive to dupilumab among those treated at a tertiary-level hospital in Italy, characterizing them according to disease severity and biomarker profiles. Patients and Methods: Real-world data were extracted from Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG) Hospital Information Systems through the implementation of the COPD DataMart. A multilevel RWE-based approach identified patients (2020-2023) aged ≥40 years on triple inhaled therapy with ≥2 moderate or ≥1 severe exacerbations. Patients were stratified according to their blood eosinophil levels (EOS), and healthcare pathways, comorbidities, symptoms, smoking status, and all-cause mortality were descriptively analyzed. Results: Among 3,279 COPD patients, 224 met inclusion criteria. Eosinophil data were available for 179 patients, of whom, 87 (48.6%) had at least one EOS ≥300 cells/μL, corresponding to 38.8% (87/224) of the total cohort. Patients with EOS ≥300 had a median of 4 EOS measurements/year, with a median value of 210 [interquartile ranges 130-335] cells/μL. Compared with EOS <300, they showed a higher inpatient origin (23.0% vs 12.2%, p=0.005), greater comorbidity burden (71.3% cardiovascular, 59.8% metabolic, and 50.6% of other comorbidities), numerically higher all-cause mortality although not statistically significant (19.5% vs 13.0%, p=0.437), and higher annual hospital contacts (4.5 vs 3.0, p<0.001). Conclusion: This real-world exploratory study identified a subgroup of patients with severe COPD within a tertiary-care setting and suggested that eosinophil monitoring may contribute to guide targeted therapeutic strategies, including emerging biological therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.